Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial.

Name: Αlpha¹ Rigor Record — Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial.
Item: Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial.
Rating: 100
Author: Αlpha¹

Colhoun HM, Lingvay I, Brown PM, Deanfield J, Brown-Frandsen K, Kahn SE, Plutzky J, Node K, Parkhomenko A, Rydén L, Wilding JPH, Mann JFE, Tuttle KR, Idorn T, Rathor N, Lincoff AM

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3★ (Adequate), 0 critical, 0 high issues for “Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced4 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions3

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a rigorously conducted and transparently reported secondary analysis of a large randomized controlled trial. The scientific premise is well-supported, the design is appropriate, and the statistical analysis is sound with exact p-values and confidence intervals. Minor reporting gaps (e.g., explicit randomization method, power analysis for secondary outcomes, reporting guideline statement) and copyedit issues (unit inconsistencies, ambiguous phrasing) are present but do not undermine the overall validity.

Both reviewers classified the study as interventional, and this was adopted. The evaluation covered the full text of the published paper, including supplementary tables referenced. The statistics verification covered only 9 of the reported tests/effect estimates (those with test statistics + df or effect estimates + CI); other p-values and resampling-based tests were not machine-verified. The citation check found no retracted or non-existent references. The reproducibility check confirmed the data access link is live.

10 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 9 tests: 9 consistent, 0 inconsistent; 9 via agent-written checks.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions8 pass

The introduction cites multiple lines of evidence: obesity as a risk factor for CKD, Mendelian randomization studies suggesting causality, and meta-analyses of GLP-1RA trials showing kidney benefits in diabetes. The rationale for studying semaglutide in non-diabetic obesity is clearly stated. Limitations of prior work (e.g., lack of data in non-diabetic populations) are explicitly addressed as the gap this study fills.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with extensive prior work and a logical rationale linking obesity to CKD and GLP-1RAs to potential kidney benefits.

Evidence

direct quote[Introduction, paragraph 1]

“Mendelian randomization studies found evidence that the association between overweight and obesity with CKD is causal.”